These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Caspofungin in the replacement of amphotericin B in the treatment of fungal diseases]. Yang W; He B Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(1):53. PubMed ID: 15808079 [No Abstract] [Full Text] [Related]
25. Drug-drug interactions of antifungal agents and implications for patient care. Gubbins PO; Amsden JR Expert Opin Pharmacother; 2005 Oct; 6(13):2231-43. PubMed ID: 16218884 [TBL] [Abstract][Full Text] [Related]
26. Antifungal drug resistance to azoles and polyenes. Masiá Canuto M; Gutiérrez Rodero F Lancet Infect Dis; 2002 Sep; 2(9):550-63. PubMed ID: 12206971 [TBL] [Abstract][Full Text] [Related]
27. Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent. Koss T; Bagheri B; Zeana C; Romagnoli MF; Grossman ME J Am Acad Dermatol; 2002 Jun; 46(6):945-7. PubMed ID: 12063497 [TBL] [Abstract][Full Text] [Related]
29. Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin. Maschmeyer G; Glasmacher A Mycoses; 2005 Jul; 48(4):227-34. PubMed ID: 15982202 [TBL] [Abstract][Full Text] [Related]
30. In vitro interaction of itraconazole with amphotericin B, caspofungin, and terbinafine against clinical isolates of Trichosporon asahii. Li H; Qiao J; Wan Z; Zhang J Mycopathologia; 2011 May; 171(5):345-8. PubMed ID: 21153882 [TBL] [Abstract][Full Text] [Related]
32. Caspofungin acetate: an antifungal agent. Hoang A Am J Health Syst Pharm; 2001 Jul; 58(13):1206-14; quiz 1215-7. PubMed ID: 11449878 [TBL] [Abstract][Full Text] [Related]
33. The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates. Mario DA; Denardi LB; Bandeira LA; Antunes MS; Santurio JM; Severo LC; Alves SH Mem Inst Oswaldo Cruz; 2012 May; 107(3):433-6. PubMed ID: 22510843 [TBL] [Abstract][Full Text] [Related]
34. In vitro activities of a wide panel of antifungal drugs against various Scopulariopsis and Microascus species. Skóra M; Bulanda M; Jagielski T Antimicrob Agents Chemother; 2015 Sep; 59(9):5827-9. PubMed ID: 26100698 [TBL] [Abstract][Full Text] [Related]
35. In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital. Arikan S; Sancak B; Hascelik G Med Mycol; 2005 Mar; 43(2):171-8. PubMed ID: 15832560 [TBL] [Abstract][Full Text] [Related]
36. [In vitro activity of a new semisynthetic echinocandin, micafungin, against clinical isolates of Candida species isolated in Tenri Hospital]. Komatsu M; Aihara M; Shimakawa K; Iwasaki M; Nagasaka Y; Fukuda S; Abe N; Matsuo S Jpn J Antibiot; 2003 Dec; 56(6):705-11. PubMed ID: 15007879 [TBL] [Abstract][Full Text] [Related]
38. In vitro activity of amphotericin B, itraconazole, terbinafine and 5-fluocytosine against Exophiala spinifera and evaluation of post-antifungal effects. Vitale RG; De Hoog GS; Verweij PE Med Mycol; 2003 Aug; 41(4):301-7. PubMed ID: 12964723 [TBL] [Abstract][Full Text] [Related]
39. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Cuenca-Estrella M; Gomez-Lopez A; Garcia-Effron G; Alcazar-Fuoli L; Mellado E; Buitrago MJ; Rodriguez-Tudela JL Antimicrob Agents Chemother; 2005 Mar; 49(3):1232-5. PubMed ID: 15728937 [TBL] [Abstract][Full Text] [Related]
40. Emerging moulds: epidemiological trends and antifungal resistance. Miceli MH; Lee SA Mycoses; 2011 Nov; 54(6):e666-78. PubMed ID: 21672045 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]